BEIJING: China delivered its first domestically developed mpox vaccine into clinical trials on Monday, Global Times reported.The vaccine, independently developed by the Shanghai Institute of Biological Products, a subsidy of the China National Pharmaceutical Group (Sinopharm), is based on a live, attenuated orthopoxvirus, Modified Vaccinia Ankara (MVA).According to the institute, the MVA strain has proved its safety and efficacy as a candidate vector for vaccination. The MVA mpox vaccine is produced using a mature cell factory production process, which is stable and reliable in quality.Preclinical studies have shown its safety and its ability to generate effective immune protection against mpox virus in non-human primate models.In August, the World Health Organisation (WHO) declared mpox in the Democratic Republic of the Congo (DRC) and neighbouring countries to be a Public Health Emergency of International Concern, the WHO's highest-level alert, along with the emergence and rapid spread of a new viru s strain in DRC named clade 1b.Source: Emirates News Agency
Recent Posts
